Fate Therapeutics, Inc.
2.11USD
+0.0200 (+0.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on FATE.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.26▲ | -$0.26 | 4 | 2 |
| Next quarter | -$0.27▲ | -$0.28 | 3 | 3 |
| Current year | -$1.02▲ | -$1.03 | 4 | 2 |
| Next year | -$0.97▲ | -$0.99 | 3 | 1 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.26 | -$0.25 | +0.01 (+2.6%) |
| 2026-03-31 | -$0.28 | -$0.26 | +0.02 (+5.5%) |
| 2025-12-31 | -$0.27 | -$0.27 | +0.00 (+0.5%) |
| 2025-09-30 | -$0.28 | -$0.27 | +0.01 (+4.3%) |
137 ratings from 28 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Piper Sandler | Reiterated | Overweight | $6 $8 | Aug 14, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $2.5 $3.5 | Aug 14, 2026 |
| Wedbush | Reiterated | Outperform | $7 | Aug 14, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $7 | Jun 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $5 $7 | May 4, 2026 |
| HC Wainwright & Co. | Upgraded from Neutral | Buy | $5 | Oct 31, 2025 |
| Wedbush | Upgraded from Neutral | Outperform | $5 $7 | Oct 27, 2025 |
| Needham | Reiterated | Hold | — | Oct 27, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $4 $2.5 | Aug 13, 2025 |
| Needham | Reiterated | Hold | — | Jun 12, 2025 |
| Barclays | Maintained | Overweight | $10 $2 | May 14, 2025 |
| Baird | Maintained | Neutral | $5 $4 | May 14, 2025 |
| Needham | Reiterated | Hold | — | May 14, 2025 |
| Stifel | Maintained | Hold | $5 $3 | Mar 6, 2025 |
| Wedbush | Reiterated | Neutral | $5 | Mar 6, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $5 $4 | Mar 6, 2025 |
| Needham | Reiterated | Hold | — | Mar 6, 2025 |
| Needham | Reiterated | Hold | — | Nov 19, 2024 |
| Needham | Reiterated | Hold | — | Nov 13, 2024 |
| HC Wainwright & Co. | Reiterated | Neutral | $5 | Aug 22, 2024 |
| Needham | Reiterated | Hold | — | Aug 14, 2024 |
| Piper Sandler | Upgraded from Neutral | Overweight | $4 $6 | Jun 17, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $7 $5 | May 16, 2024 |
| Canaccord Genuity | Maintained | Buy | $11 $9 | May 10, 2024 |
| BMO Capital | Maintained | Market Perform | $7 $6 | May 10, 2024 |
23 filings from 7 insiders · 3 buy / 4 sell over 6m
Officers and directors of FATE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TAHL CINDY ROfficer | Sell | 38.8k | $2.46 | $95k | Aug 4, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 43.9k | $2.46 | $108k | Aug 4, 2026 |
| TAHL CINDY ROfficer | Sell | 25.6k | $1.88 | $48k | May 20, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 28.9k | $1.88 | $54k | May 20, 2026 |
| TAHL CINDY ROfficer | Exercise | 166.7k | $1.05 | $208k | May 6, 2026 |
| EPSTEIN ROBERT SDirector | Exercise | 25.0k | $1.69 | $42k | May 5, 2026 |
| RASTETTER WILLIAM HDirector | Exercise | 25.0k | $1.69 | $42k | May 5, 2026 |
| TAHL CINDY ROfficer | Grant | 100.0k | — | — | Jan 15, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Grant | 335.0k | — | — | Jan 15, 2026 |
| ADAWI KAMALChief Financial Officer | Grant | 25.0k | — | — | Jan 15, 2026 |
| TAHL CINDY ROfficer | Sell | 10.6k | $1.06 | $11k | Jan 9, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 5.2k | $1.07 | $6k | Jan 9, 2026 |
| ADAWI KAMALChief Financial Officer | Grant | 75.0k | — | — | Oct 20, 2025 |
| TAHL CINDY ROfficer | Sell | 9.0k | $1.06 | $10k | Aug 4, 2025 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 14.5k | $1.06 | $15k | Aug 4, 2025 |
| TAHL CINDY ROfficer | Grant | 70.0k | — | — | Jan 15, 2025 |
| BRESSI JEROME CHARLESOfficer | Grant | 65.0k | — | — | Jan 15, 2025 |
| TAHL CINDY ROfficer | Sell | 5.7k | $1.55 | $9k | Jan 10, 2025 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 8.7k | $1.54 | $13k | Jan 10, 2025 |
| BRESSI JEROME CHARLESOfficer | Sell | 6.0k | $1.55 | $9k | Jan 10, 2025 |
No analyst notes on FATE yet.
Members whose judged calls on FATE have played out most reliably.
No settled calls on FATE yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 4 | 6 | 0 | 0 | Buy2.45 |
| 1 mo ago | 1 | 4 | 6 | 0 | 0 | Buy2.45 |
| 2 mo ago | 1 | 4 | 6 | 0 | 0 | Buy2.45 |
| 3 mo ago | 1 | 5 | 6 | 0 | 0 | Buy2.42 |